#3. John C. Reed, M.D., Ph.D.

#2. Richard A. Lerner, M.D.11

Title: President and CEO, 1991–2012;11 Researcher, Skaggs Institute for Chemical Biology, where he is an Institute Professor and the Lita Annenberg Hazen Professor of Immunochemistry, 2012–present; director of predecessor organization, 1987–1991

Institution: The Scripps Research Institute

FY ending September 30, 2012: $1,370,560

FY ending September 30, 2011: $1,370,494

% Change: 0.005%

#1. Stephen M. Prescott, M.D.

Notes:1 Also holds faculty positions as Robert W. and Linda L. Mahley Distinguished Professor, and as professor of medicine at the University of California, San Francisco (UCSF).2 Dr. Liu took office as president and CEO in January 2012.3 HUGO is headquartered in Singapore and thus is not subject to U.S. disclosure requirements.4 Holds the additional positions of Head, Melanoma Therapeutics Lab, and Professor, Genetic Basis of Human Disease Division.5 Difference in tax year period follows a decision by TGen to adopt a tax year ending on December 31, effective in 2012. The change followed the termination of the alliance and affiliation agreement between TGen and the Van Andel Research Institute effective March 12, 2012. That agreement took effect December 1, 2009, and led to TGen changing the end date of its tax year from June 30 to November 30, effective in 2010.6 During TGen’s alliance with the Van Andel Research Institute (VAI), Jeffrey Trent held positions with both institutions, serving as both president and scientific director of TGen, as well as serving president and research director of VAI. He no longer holds the VAI position.7 Has served as President since April 2010, and as interim CEO since January 2013, when John C. Reed, M.D., Ph.D., resigned to accept position as Head of Roche Pharma Research and Early Development, and member of Roche’s Corporate Executive Committee. See: http://beaker.sanfordburnham.org/2013/01/john-reed-resigns-ceo-accepts-roche/8 Also serves as CEO of BioMed Valley Discoveries, the organization responsible for the translation of the Institute’s basic biomedical discoveries into therapeutic applications.9 Also continues his research on the biochemistry of gene regulation as a group leader at HHMI’s Janelia Farm Research Campus, as well as at University of California, Berkeley.10 Resigned as CEO in January 2013 to accept position as Head of Roche Pharma Research and Early Development (pRED), and member of Roche’s Executive Committee. His duties have since been assumed on an interim basis by Kristiina Vuori, M.D., Ph.D., who holds the position of president and interim CEO. See: http://beaker.sanfordburnham.org/2013/01/john-reed-resigns-ceo-accepts-roche/11 Succeeded by Michael A. Marletta, Ph.D., as President and CEO on January 1, 2012. Dr. Marletta’s total compensation for the fiscal year ending September 30, 2012, was $446,034.12 More than half of his total compensation is accounted for in two categories—$205,148 in “bonus & incentive compensation” and $825,275 in “other compensation.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.1%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.